Fig. 1: Luc-90-CAR-T demonstrates efficacy in a high tumor burden systemic myeloma model. | Leukemia

Fig. 1: Luc-90-CAR-T demonstrates efficacy in a high tumor burden systemic myeloma model.

From: CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells

Fig. 1

A CS1 epitopes (B) CAR constructs (C) Luc90-CAR-T and CD19-CAR-T effectors were incubated with 51chromium labeled MM.1S-CG or MM.1S-ΔCS1 target cells for 4 h. Chromium release was used to assess killing. D Kaplan–Meier survival analysis of mice engrafted with either 5 × 105 MM.1S-CG or MM.1S-CG-ΔCS1cells and treated with nothing, Luc90-CAR-T, or CD19-CAR-T. Median survival for mice treated with Luc90 CS1-CAR-T was not reached (n = 28), while median survival of CD19-CAR-T and untreated mice was 46 and 42 days, respectively (n = 13 each). Median survival of mice engrafted with MM.1S-CG ΔCS1 and treated with Luc90-CAR-T was 50 days (n = 2). E, F Representative bioluminescent imaging of mice. In (E), each line represents one mouse and in (F), normalized BLI images are shown. The mouse experiment is representative of four separate experiments (MM.1S-CG engrafted: CD19 CAR-T n = 16, Luc90 CS1 CAR-T n = 28, Untreated n = 8; MM.1S-CG ΔS1 CD19 CAR-T n = 4, Luc90 CS1-CAR-T n = 2). G Percentages of CAR + (CD34 + ) CD4 and CD8 in NTD, CD19-CAR-T and Luc90-CAR-T cultures.

Back to article page